Latest Wave of ETF Filings Target Crypto Yield With Leverage and Staking

ccn.comPublicado a 2025-10-17Actualizado a 2025-10-17

Key Takeaways

Asset managers are looking to expand beyond vanilla crypto ETFs.
The latest proposals incorporate advanced strategies based on staking and leverage.
Ark Invest has also proposed Bitcoin ETFs with downside protections.

The first exchange-traded funds (ETFs) with crypto exposure relied on futures contracts. Then, in 2024, stock exchanges welcomed spot ETFs.

In the next wave of financial innovation, fund managers want to ramp up earning potential with staking and leverage.

Top Crypto Tax Accounting Software

CoinTracker

promotions

Trusted, Secure & Crypto Friendly

Coins

–

Claim Offer

TokenTax

promotions

Save 10% on TokenTax with multi-year purchases

Coins

–

Claim Offer

CoinLedger

promotions

Earn $100+ per referral who signs up with your link

Coins

–

Claim Offer

Chasing Staked Crypto Exposure

Ever since the launch of the first spot Ether ETFs last year, the prospect that funds could stake assets to grow their holdings has been tantalizing.

Asset managers like Ark Invest, Fidelity, and 21Shares did initially propose the concept in early 2024, but staking proved to be a regulatory hurdle, and it was absent when the first Ethereum ETFs launched later that year.

This summer, ETF providers, including BlackRock, filed to amend their respective ETH funds to incorporate staking.

Many of the altcoin ETF applications currently awaiting approval also include language on staking.

But so far, none of these have received the regulatory greenlight.

Regulatory Issues

The problem ETF hopefuls face is that staking rewards complicate the view of cryptocurrencies as commodities currently sanctioned by the SEC.

Compared to holding static assets, staking delivers active returns, which could be perceived as an investment contract under the Howey Test.

However, VanEck’s latest ETF application could potentially get around this.

On Oct. 16, the fund manager filed an S-1 registration with the SEC for an ETF holding Lido Staked Ethereum (stETH).

With Lido, regards are baked into the stETH–ETH exchange rate. This means ETFs wouldn’t have to operate their own validators or rely on a third-party staking service.

Bringing Leverage to Crypto ETFs

Beyond staking, ETF issuers are exploring other opportunities outside of vanilla investment strategies.

On Oct. 16, 21Shares filed to list a HYPE fund with 2x long leverage.

Volatility Shares is also expanding into leveraged crypto ETFs, filing a series of applications for funds that would invest in BTC, ETH, SOL, and XRP margin contracts.

Leveraged crypto ETFs are intended to deliver higher returns to investors.

Contracts would settle on a daily basis. Because the proposed funds are heavily invested in the respective assets, if the market rises, investors will amplify their returns; however, if it falls, their losses will multiply.

Another approach to maximizing returns is seen in Ark Invest’s proposal for a “Bitcoin Yield” ETF. The fund would invest in BTC options and premiums, with Ark strategists employed to predict the market.

Ark has also filed for two “DIET” Bitcoin ETFs that would offer downside protection with earning potential based on BTC’s quarterly price movements.

Lecturas Relacionadas

CFTC Chairman Reveals Plans: The Next Frontier, Crypto, Computing Power Markets, and Prediction Markets

CFTC Chairman Michael S. Selig outlined a regulatory roadmap targeting three new frontiers: crypto assets, AI compute power, and prediction markets. Regarding crypto, while preferring comprehensive legislation like the CLARITY Act, the CFTC is preparing to use its existing authority to potentially designate platforms as regulated "Crypto Asset Markets" if Congress fails to act. For AI, the focus is on developing markets for GPU compute power, treating it as a tradable commodity for price discovery and risk management. For prediction markets, the CFTC is moving beyond the "gambling" debate to propose specific rules for event contracts, focusing on product listing standards, market manipulation prevention, and retail investor protection. The chairman emphasized a consistent philosophy: establishing clear regulatory frameworks is essential for fostering responsible innovation in these emerging financial areas.

marsbitHace 34 min(s)

CFTC Chairman Reveals Plans: The Next Frontier, Crypto, Computing Power Markets, and Prediction Markets

marsbitHace 34 min(s)

Nethermind Moves Cross-Chain Node Operations From LayerZero To Chainlink CCIP

Ethereum engineering firm Nethermind has ceased its participation as a Decentralized Verifier Network (DVN) participant for LayerZero and will now operate its cross-chain node operations on Chainlink's Cross-Chain Interoperability Protocol (CCIP). As a well-known infrastructure provider, Nethermind's decision adds a credible name to CCIP's operator set, bolstering Chainlink's positioning as a secure, institutionally-focused interoperability standard. The move highlights the increasing scrutiny on cross-chain security and the importance of trusted node operators. However, it represents one major provider's infrastructure choice based on its own priorities and risk assessment, not a market-wide replacement. LayerZero remains a prominent player in the competitive cross-chain messaging landscape. The significance of Nethermind's migration will be clearer if other operators follow suit, potentially strengthening CCIP's position. For now, it signifies a notable credibility boost for Chainlink's cross-chain offering while the broader interoperability race continues.

bitcoinistHace 37 min(s)

Nethermind Moves Cross-Chain Node Operations From LayerZero To Chainlink CCIP

bitcoinistHace 37 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHace 39 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHace 39 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHace 40 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHace 40 min(s)

With 319 Million Shares Facing Lifting of Trading Restrictions, Why Did SpaceX Drop Nearly 5% Intraday?

SpaceX's second round of post-IPO lock-up shares was lifted on August 20th, with approximately 319 million shares held by insiders becoming eligible for trading. The sudden potential expansion of the tradable share float led to a near 5% intraday drop in the stock price, as short-term supply pressure temporarily outweighed the market's long-term enthusiasm for its rocket, satellite, and AI infrastructure businesses.

Hace 1 hora(s)

Trading

Spot